XM tidak memberikan layanan kepada penduduk Amerika Serikat.
G
G

Gilead


Berita

U.S. STOCKS Unity Software, Viking Holdings, Adobe

BUZZ-U.S. STOCKS ON THE MOVE-Unity Software, Viking Holdings, Adobe Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were mixed in choppy trading on Thursday after higher-than-expected producer prices data kept a smaller 25-basis point rate cut by the Fed firmly on the table, while Moderna slumped following a downbeat revenue forecast.
A
G
K
M
U
U
U
D
A

U.S. STOCKS Gold miners, silver miners, Warner Bros Discovery

BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street was little changed on Thursday after hot producer prices data kept a smaller, 25-basis-point interest-rate cut by the Federal Reserve firmly on the table, while vaccine maker Moderna's shares slumped following a downbeat revenue forecast.
G
K
M
U
U
D
W
A

Gilead rises as its long-acting HIV drug shows promise compared with daily Truvada

BUZZ-Gilead rises as its long-acting HIV drug shows promise compared with daily Truvada ** Shares of drugmaker Gilead GILD.O rise nearly 2% to $82.55 ** Co says its HIV injectable drug lenacapavir reduced HIV infections by 96% and was superior to daily pill Truvada in second late-stage trial ** The study included cisgender men, transgender men, tra
G

U.S. Cintas, Sprouts Farmers Market, Voya Financial

U.S. RESEARCH ROUNDUP-Cintas, Sprouts Farmers Market, Voya Financial Sept 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cintas Corp, Sprouts Farmers market and Voya Financial, on Thursday. HIGHLIGHTS * Ally Financial Inc ALLY.N : RBC cuts target price to $40 from $49 * Cintas Corp CTAS.O : CFRA adjusts target price to $170 from $645 to reflect 4-for-1 stock split * Gilead GILD.O : Raymond James raises target pri
C
E
G
L
N
P
S
E
A
D
E
L

US FDA staff questions confirmatory trial data for Intercept's liver disease drug

UPDATE 2-US FDA staff questions confirmatory trial data for Intercept's liver disease drug Rewrites paragraph 1, adds details from FDA and company's briefing documents in paragraphs 7, 8 and 9 and background in paragraphs 10 and 11 Sept 11 (Reuters) - Staff reviewers at the U.S. Food and Drug Administration said on Wednesday a confirmatory trial did not show the effectiveness of Intercept's liver disease drug, which received the health regulator's accelerated nod in 2016. Under the accelerated p
G

U.S. Centerspace, Neurocrine Biosciences, 1-800-Flowers.com

U.S. RESEARCH ROUNDUP-Centerspace, Neurocrine Biosciences, 1-800-Flowers.com Aug 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Centerspace, Neurocrine Biosciences and Veeva Systems, on Thursday. HIGHLIGHTS * Air Products APD.N : Berenberg raises target price to $275 from $240 * Centerspace CSR.N : Raymond James raises target price to $82 from $75 * Neurocrine Biosciences Inc NBIX.O : Piper Sandler raises to over
A
G
M
N
N
S
A
D
E
E
A
E
P

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Gilead Sciences Inc GILD.OQ +2.0% Vertex Pharmaceuticals Inc VRTX.OQ +1.8% Copart Inc CPRT.OQ +1.2% Verisk Analytics Inc VRSK.OQ +1.2% Old Dominion Freight Line Inc ODFL.OQ +1.1% Bottom Performers Percent Change Super Micro Computer Inc SMCI.OQ -25.1% PDD Holdings Inc PDD.OQ -6.3% Arm Holdings PLC ARM.OQ -5.5% Lululemon Athletica Inc LULU.OQ -4.4% Micron Technology Inc MU.OQ -4.3%
G
L
M
V
V
U
P
C
O

S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT S&P 500 .SPX Top Performers Percent Change Insulet Corp PODD.OQ +3.9% Bristol-Myers Squibb Co BMY.N +2.9% Bio Rad Laboratories Inc BIO.N +2.1% Gilead Sciences Inc GILD.OQ +2.0% International Flavors & Fragrances Inc IFF.N +1.9% Bottom Performers Percent Change Super Micro Compu
G
L
M
U
I

U.S. Alamo Group, Cognizant, Moderna

CORRECTED-U.S. RESEARCH ROUNDUP- Alamo Group, Cognizant, Moderna Corrects ESS Tech Inc entry to say Deutsche Bank adjusts PT to $9 from $0.90 to reflect 1-for-15 reverse stock split Aug 28 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alamo Group, Cognizant and Moderna, on Wednesday.
C
G
M
S
U
C
E
P

PANTHERX® RARE PARTNERING WITH GILEAD SCIENCES, INC. FOR DISTRIBUTION OF LIVDELZI®

BRIEF-PANTHERX® RARE PARTNERING WITH GILEAD SCIENCES, INC. FOR DISTRIBUTION OF LIVDELZI® Aug 16 (Reuters) - PANTHERx Rare Pharmacy- PANTHERX® RARE PARTNERING WITH GILEAD SCIENCES, INC. FOR DISTRIBUTION OF LIVDELZI®
G

Incyte's blood cancer drug succeeds late-stage trial

Incyte's blood cancer drug succeeds late-stage trial Aug 15 (Reuters) - Incyte INCY.O said on Thursday its drug met the main goal in a late-stage trial evaluating it in patients with a form of blood cancer. The company said its drug Monjuvi, combined with Bristol Myers Squibb's BMY.N drug, Revlimid, and Biogen's BIIB.O Rituxan achieved progression free survival in patients with follicular lymphoma (FL), when compared to Rituxan and Revlimid alone.
B
G
I
N

U.S. Allstate, bluebird bio , Vicinity Motor

U.S. RESEARCH ROUNDUP-Allstate, bluebird bio , Vicinity Motor Aug 15 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Allstate, bluebird bio and Vicinity Motor, on Thursday. HIGHLIGHTS * Allstate Corp ALL.N : CFRA cuts to hold from buy * Autodesk Inc ADSK.O : Baird raises target price to $295 from $289 * bluebird bio Inc BLUE.O : JP Morgan cuts to neutral from overweight * Provident Financial Services Inc PFS.N : KBW
A
A
C
G
I
K
D
A

Gilead gets US FDA approval for inflammatory liver disease drug

UPDATE 3-Gilead gets US FDA approval for inflammatory liver disease drug Adds pricing in paragraph 4, company comments in paragraphs 6-7, details on common symptom in paragraphs 10-12 By Puyaan Singh and Leroy Leo Aug 14 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' GILD.O liver disease treatment, Livdelzi, which it gained through a $4.3 billion buyout of CymaBay Therapeutics earlier this year.
G
I

FDA Approves Gilead's Livdelzi For Primary Biliary Cholangitis - Website

BRIEF-FDA Approves Gilead's Livdelzi For Primary Biliary Cholangitis - Website Aug 14 (Reuters) - FDA: FDA APPROVES GILEAD'S LIVDELZI FOR PRIMARY BILIARY CHOLANGITIS - WEBSITE Further company coverage: GILD.O
G

US FDA approves Gilead's liver disease drug

US FDA approves Gilead's liver disease drug Aug 14 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences' GILD.O drug for a chronic and potentially fatal liver disease that mostly affects women. The disease, primary biliary cholangitis (PBC), causes inflammation of the small bile ducts in the liver and can eventually destroy them.
G

Gilead Sciences Inc reports results for the quarter ended in June - Earnings Summary

Gilead Sciences Inc reports results for the quarter ended in June - Earnings Summary Gilead Sciences Inc GILD.OQ reported quarterly adjusted earnings of $2.01​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $1.66. The mean expectation of twenty three analysts for the quarter was for earnings of $1.60 per share.
G

Gilead quarterly profit beats Street estimates, revenue up 5%

UPDATE 1-Gilead quarterly profit beats Street estimates, revenue up 5% Adds analyst comment, share price, paragraphs 4-6 By Deena Beasley Aug 8 (Reuters) - Gilead Sciences GILD.O on Thursday reported second-quarter profit that handily beat Wall Street estimates, driven by lower operating expenses and higher product sales, and the drugmaker raised its outlook for full-year earnings.
G

Gilead quarterly profit beats Street estimates, revenue up 5%

Gilead quarterly profit beats Street estimates, revenue up 5% By Deena Beasley Aug 8 (Reuters) - Gilead Sciences GILD.O on Thursday reported second-quarter profit that handily beat Wall Street estimates, driven by lower operating expenses and higher product sales, and the drugmaker raised its outlook for full-year earnings. The Foster City, California-based company posted a quarterly profit of $2.01 per share excluding items, on revenue of $7 billion, up from $1.34 a share and revenue of $6.6 bi
G

Gilead Q2 EPS USD 1.29

BRIEF-Gilead Q2 EPS USD 1.29 Aug 08 (Reuters) - Gilead Q2 product sales USD 6,912 million. Q2 operating income USD 2,644 million Q2 pretax profit USD 2,053 million vs. IBES estimate USD 2,593 million Q2 net income USD 1,614 million Q2 basic EPS USD 1.29
G

Merck stops testing combo drug for lung cancer

UPDATE 1-Merck stops testing combo drug for lung cancer Adds details in paragraphs 2 and 6, background throughout Aug 8 (Reuters) - Merck MRK.N said on Thursday it had discontinued a trial testing a combination immunotherapy treatment in patients with a type of lung cancer after an interim analysis showed the drug was unlikely to succeed. The patients tested with a combination of its experimental drug, vibostolimab, with Keytruda experienced a higher rate of immune-related side effects, Merck sa
G



Kondisi

Aset Populer

Pengungkapan: Entitas XM Group menyediakan layanan khusus eksekusi dan akses ke Fasilitas Trading Online kami, yang memungkinkan Anda untuk melihat dan/atau menggunakan konten yang tersedia pada atau melalui situs, yang tidak untuk mengubah atau memperluas, serta tidak mengubah atau memperluas hal tersebut. Akses dan penggunaan ini selalu sesuai dengan: (i) Syarat dan Ketentuan; (ii) Peringatan Risiko; dan (iii) Pengungkapan Penuh. Oleh karena itu, konten disediakan hanya sebagai informasi umum. Anda juga harus ketahui bahwa konten Fasilitas Trading Online kami bukan sebagai ajakan atau tawaran untuk untuk melakukan transaksi apa pun di pasar finansial. Trading di pasar finansial mana pun melibatkan tingkat risiko yang signifikan pada modal Anda.

Semua materi yang diterbitkan di Fasilitas Trading Online kami hanya untuk tujuan edukasi/informasi dan tidak boleh mengandung nasihat dan rekomendasi finansial, pajak investasi atau trading, catatan harga trading kami, penawaran, permintaan, transaksi dalam instrumen finansial apa pun atau promo finansial untuk Anda yang tidak diminta.

Konten pihak ketiga apa pun, serta konten yang disiapkan oleh XM, seperti opini, berita, riset, analisis, harga, informasi lain atau link ke situs pihak ketiga yang tersedia "sebagaimana adanya", sebagai komentar pasar umum dan bukan menjadi nasihat investasi. Sejauh konten apa pun ditafsirkan sebagai penelitian investasi, Anda harus memperhatikan dan menerima bahwa konten tersebut tidak dimaksudkan dan belum disiapkan sesuai dengan persyaratan hukum yang dirancang untuk mempromosikan kemandirian riset investasi dan dengan demikian akan dianggap sebagai komunikasi pemasaran di bawah hukum dan peraturan yang relevan. Mohon dipastikan bahwa Anda telah membaca dan memahami Notifikasi pada Riset Investasi Non-Independen dan Peringatan Risiko kami mengenai informasi di atas, yang dapat diakses disini.

Peringatan Resiko: Modal Anda beresiko. Produk dengan leverage mungkin tidak cocok bagi semua orang. Silahkan pertimbangkan Pengungkapan Resiko kami.